Antibiotic free enzyme production using bacteriocins
Enzymicals and Syngulon present an update about their non-exclusive license agreement of May 2020 on the use of Syngulon’s antibiotic free technology to produce enzymes. The R&D phase for the first project has ended successfully with several enzymes developed and the large-scale production has started.
There is a growing interest for antibiotic-free production of enzymes coming from our customers and Syngulon’s technology was applied in a first project for the large-scale production of diagnostic enzymes for a world leading diagnostics company that requires antibiotic-free production. Several enzymes have been successfully developed and produced internally at Enzymicals using Syngulon’s technology during the R&D and pilot phase that has now ended with the start of the large-scale production in fermenters up to 500L for these enzymes.
Dr. Erik de Vries, CEO of Enzymicals AG, states “Syngulon’s new genetic technology is easy to set up and as convenient as conventional antibiotic-based selection techniques. We are happy to have successfully ended the R&D phase with several enzymes and started the large-scale production. We are now looking at other specific developments and broader applicability of Syngulon’s bacteriocin technology for our clients.”
Guy Hélin, CEO of Syngulon, added “This is a very important milestone because the first products with our technology will soon be on the market thanks to Enzymicals and their project for a world leader in diagnostic enzymes.”
